Alchemedicine Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10.2M

  • Investors
  • 8

Alchemedicine General Information

Description

Provider of drug discovery services intended to treat diseases with unmet medical needs. The company's services actively work to create new drugs even in areas and diseases where drug discovery is seemingly difficult, enabling clients to deliver drugs that are useful to patients as soon as possible.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Tsukuba Center Building, 1-10-1 Azuma
  • Tsukuba City, 305-0031
  • Japan
+81
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 4th Floor, Tsukuba Center Building, 1-10-1 Azuma
  • Tsukuba City, 305-0031
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alchemedicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 18-Dec-2022 $10.2M Completed Generating Revenue
3. Later Stage VC (Series C) 16-Feb-2021 Completed Generating Revenue
2. Early Stage VC (Series B) 18-Oct-2019 $2.02M $2.4M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 14-Jun-2019 $385K $385K Completed Pre-Clinical Trials
To view Alchemedicine’s complete valuation and funding history, request access »

Alchemedicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
D Shares
C Shares
B Shares 39,544 $39.9 $39.9 1x $39.9 17.48%
A Shares 15,000 $20.31 $20.31 1x $20.31 6.63%
To view Alchemedicine’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alchemedicine Patents

Alchemedicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026014456-A1 Compound, complement factor d inhibitor, and pharmaceutical composition Pending 10-Jul-2024
WO-2024101440-A1 Compound, endothelin a receptor antagonist, angiotensin ii type 1 receptor antagonist, and pharmaceutical composition Inactive 11-Nov-2022
JP-2025183466-A Compound, endothelin receptor antagonist, angiotensin ii type 1 receptor antagonist, and pharmaceutical composition Pending 11-Nov-2022
AU-2023257780-A1 Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug Pending 22-Apr-2022
US-20250084036-A1 Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug Pending 22-Apr-2022 C07D213/56
To view Alchemedicine’s complete patent history, request access »

Alchemedicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alchemedicine Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Mizuho Capital Venture Capital Minority
Beyond Next Ventures Venture Capital Minority
Enjoyor Investment Corporate Venture Capital Minority
Jafco Venture Capital Minority
Joyo Capital Partners Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Alchemedicine FAQs

  • When was Alchemedicine founded?

    Alchemedicine was founded in 2019.

  • Where is Alchemedicine headquartered?

    Alchemedicine is headquartered in Tsukuba City, Japan.

  • What is the size of Alchemedicine?

    Alchemedicine has 3 total employees.

  • What industry is Alchemedicine in?

    Alchemedicine’s primary industry is Drug Discovery.

  • Is Alchemedicine a private or public company?

    Alchemedicine is a Private company.

  • What is the current valuation of Alchemedicine?

    The current valuation of Alchemedicine is .

  • What is Alchemedicine’s current revenue?

    The current revenue for Alchemedicine is .

  • How much funding has Alchemedicine raised over time?

    Alchemedicine has raised $19.8M.

  • Who are Alchemedicine’s investors?

    Mizuho Capital, Beyond Next Ventures, Enjoyor Investment, Jafco, and Joyo Capital Partners are 5 of 8 investors who have invested in Alchemedicine.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process